Eric Delabesse


Impact of genetic alterations on acute leukemia development


The specificities
of our research axis


Acute leukemia are cancers of the bone marrow associated with a poor prognosis, mainly sporadic, very rarely some of them having a genetic origin. The development of these cancers results from successive acquisition of mutations (generally between 1 and 5).

We are analyzing the biological mechanisms by which mutations in hematopoietic key genes (mainly PAX5 in B differentiation, GATA2 in myeloid differentiation and USP7 and CHK1 in cell cycle) reprogram normal progenitors to establish a pre-leukemic state and initiate leukemic transformation. Our team uses a multidisciplinary approach on patient samples and mouse models, using CRISPR-Cas9 mutagenesis, ex vivo and in vivo functional assays, flow cytometry, transcriptome and mutation analysis (by next generation sequencing) and high throughput drug screening.

This combined approach allows us to study normal hematopoietic development and the biology of hematopoietic stem cells as well as the oncogenic reprogramming and oncogenic process induced by genomic mutations.

This work is thus part of a fundamental and translational research, with the perspective of identifying new therapeutic agents improving the treatment of acute leukemia, in particular the targeting of leukemic stem cells.

Hematopoietic Transcription factors

Cell cycle actors

Somatic and Germline mutations

Acute Myeloid and B-cell Leukaemia (AML and B-ALL)

Myelodysplastic syndromes (MDS)

Clinical research

National registry of patients



En live

Voir plus

scientific productions

Tamburini, Jerome, Sarah Mouche, Clement Larrue, Nicolas Duployez, Audrey Bidet, Auriane Salotti, Pierre Hirsch, et al. “Very Short Insertions in the FLT3 Gene Are of Therapeutic Significance in Acute Myeloid Leukemia.” Blood Advances 7, no. 24 (December 26, 2023): 7576–80.
Faguer, Stanislas, Eric Delabesse, Carle Paul, and Marlène Pasquet. “IL-4Rα Inhibition for Severe ‘Eosinophilic Gastroenteritis, Allergy, and Anaphylaxis’ Syndrome Due to a Gain-of-Function Variant in STAT6.” Journal of Clinical Immunology 44, no. 1 (December 22, 2023): 29.
Darlington, Meryl, Pierre Sujobert, Olivier Kosmider, Damien Luque Paz, Sophie Kaltenbach, Martin Figeac, Sandrine Hayette, et al. “Targeted High-Throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France.” HemaSphere 7, no. 9 (September 2023): e943.
Pelletier, Jeoffrey, Marielle Balzano, Jérôme Destin, Camille Montersino, Marjorie C. Delahaye, Tony Marchand, Anne-Laure Bailly, et al. “Niche-Expressed Galectin-1 Is Involved in Pre-B Acute Lymphoblastic Leukemia Relapse through Pre-B Cell Receptor Activation.” IScience iScience, no. 4 (April 21, 2023): 106385.
Duployez, Nicolas, Loïc Vasseur, Rathana Kim, Laëtitia Largeaud, Marie Passet, Anaïs L’Haridon, Pierre Lemaire, et al. “UBTF Tandem Duplications Define a Distinct Subtype of Adult de Novo Acute Myeloid Leukemia.” Leukemia, April 21, 2023.
Largeaud, Laetitia, Matthew Collin, Nils Monselet, Francois Vergez, Vincent Fregona, Lise Larcher, Pierre Hirsch, et al. “Somatic Genetic Alterations Predict Haematological Progression in GATA2 Deficiency.” Haematologica, February 2, 2023.
Kim, Rathana, Hugo Bergugnat, Lise Larcher, Matthieu Duchmann, Marie Passet, Stephanie Gachet, Wendy Cuccuini, et al. “Adult Low Hypodiploid Acute Lymphoblastic Leukemia Emerges from Pre-Leukemic TP53-Mutant Clonal Hematopoiesis.” Blood Cancer Discovery, January 11, 2023, BCD-22-0154.
Canali, Alban, Inès Vergnolle, Sarah Bertoli, Laetitia Largeaud, Marie-Laure Nicolau, Jean-Baptiste Rieu, Suzanne Tavitian, et al. “Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 29, no. 1 (January 4, 2023): 134–42.
Othman, Jad, Manja Meggendorfer, Enrico Tiacci, Christian Thiede, Richard F. Schlenk, Richard Dillon, Sebastian Stasik, et al. “Overlapping Features of Therapy-Related and de NovoNPM1-Mutated AML.” Blood, December 12, 2022, blood.2022018108.
Lafage-Pochitaloff, Marina, Bastien Gerby, Véronique Baccini, Laetitia Largeaud, Vincent Fregona, Naïs Prade, Pierre-Yves Juvin, et al. “The CADM1 Tumor Suppressor Gene Is a Major Candidate Gene in MDS with Deletion of the Long Arm of Chromosome 11.” Blood Advances 6, no. 2 (January 25, 2022): 386–98.
Largeaud, Laetitia, Sarah Bertoli, Emilie Bérard, Suzanne Tavitian, Muriel Picard, Stéphanie Dufrechou, Naïs Prade, et al. “Genomic Landscape of Hyperleukocytic Acute Myeloid Leukemia.” Blood Cancer Journal 12, no. 1 (January 5, 2022): 4.
Veiga, Diogo F. T., Mathieu Tremblay, Bastien Gerby, Sabine Herblot, André Haman, Patrick Gendron, Sébastien Lemieux, et al. “Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.” Frontiers in Immunology 13 (2022): 867443.
Récher, Christian, Christoph Röllig, Emilie Bérard, Sarah Bertoli, Pierre-Yves Dumas, Suzanne Tavitian, Michael Kramer, et al. “Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from European Registries.” Leukemia, November 13, 2021.
Galtier, Jean, Camille Alric, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Audrey Bidet, Eric Delabesse, et al. “Intermediate-Dose Cytarabine or Standard-Dose Cytarabine plus Single-Dose Anthracycline as Post-Remission Therapy in Older Patients with Acute Myeloid Leukemia: Impact on Health Care Resource Consumption and Outcomes.” Blood Cancer Journal 11, no. 11 (November 13, 2021): 180.
Fregona, Vincent, Manon Bayet, and Bastien Gerby. “Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells.” Cancers 13, no. 21 (November 2, 2021): 5511.
Pavone, Rossana, Hélène Pacquement, Marlène Pasquet, Hélène Sudour-Bonnange, Fédéric Hameury, Sabine Sarnacki, Pascal Chastagner, et al. “Childhood Ovarian Nonseminomatous Germ Cell Tumors: A Highly Curable Disease with Few Long-Term Treatment-Related Toxicities-Results of the French TGM95 Study.” International Journal of Cancer 149, no. 9 (November 1, 2021): 1705–12.
Singh, Preeti, Maninder Heer, Anastasia Resteu, Aneta Mikulasova, Mojgan Reza, Laetitia Largeaud, Stephanie Dufrechou, et al. “GATA2 Deficiency Phenotype Associated with Tandem Duplication GATA2 and Over-Expression of GATA2-AS1.” Blood Advances, October 12, 2021, bloodadvances.2021005217.
Magnol, Marion, Loukianos Couvaras, Yannick Degboé, Eric Delabesse, Cristina Bulai-Livideanu, Adeline Ruyssen-Witrand, and Arnaud Constantin. “VEXAS Syndrome in a Patient with Previous Spondyloarthritis with a Favourable Response to Intravenous Immunoglobulin and Anti-IL17 Therapy.” Rheumatology (Oxford, England) 60, no. 9 (September 1, 2021): e314–15.
Bouvier, Anne, Jean-François Hamel, Jacques Delaunay, Eric Delabesse, Pierre-Yves Dumas, Marie-Pierre Ledoux, Pierre Peterlin, et al. “Molecular Classification and Prognosis in Younger Adults with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics Treated or Not by Gemtuzumab Ozogamycin: Final Results of the GOELAMS/FILO Acute Myeloid Leukemia 2006-Intermediate-Risk Trial.” European Journal of Haematology 107, no. 1 (July 2021): 111–21.
Largeaud, Laetitia, Pascale Cornillet-Lefebvre, Jean-François Hamel, Pierre-Yves Dumas, Naïs Prade, Stéphanie Dufrechou, Julien Plenecassagnes, et al. “Lomustine Is Beneficial to Older AML with ELN2017 Adverse Risk Profile and Intermediate Karyotype: A FILO Study.” Leukemia 35, no. 5 (May 2021): 1291–1300.
Duployez, Nicolas, Laura A. Jamrog, Vincent Fregona, Camille Hamelle, Laurène Fenwarth, Sophie Lejeune, Nathalie Helevaut, et al. “Germline PAX5 Mutation Predisposes to Familial B-Cell Precursor Acute Lymphoblastic Leukemia.” Blood 137, no. 10 (March 11, 2021): 1424–28.
Cartel, Maëlle, Pierre-Luc Mouchel, Mathilde Gotanègre, Laure David, Sarah Bertoli, Véronique Mansat-De Mas, Arnaud Besson, Jean-Emmanuel Sarry, Stéphane Manenti, and Christine Didier. “Inhibition of Ubiquitin-Specific Protease 7 Sensitizes Acute Myeloid Leukemia to Chemotherapy.” Leukemia 35, no. 2 (February 2021): 417–32.
Bories, Pierre, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, et al. “Impact of TP53 Mutations in Acute Myeloid Leukemia Patients Treated with Azacitidine.” Edited by Francesco Bertolini. PLOS ONE 15, no. 10 (October 1, 2020): e0238795.
Dumas, Pierre-Yves, Sarah Bertoli, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Jean Galtier, Camille Alric, et al. “Delivering HDAC over 3 or 5 Days as Consolidation in AML Impacts Health Care Resource Consumption but Not Outcome.” Blood Advances 4, no. 16 (August 25, 2020): 3840–49.
Fagnan, Alexandre, Frederik Otzen Bagger, Maria-Riera Piqué-Borràs, Cathy Ignacimouttou, Alexis Caulier, Cécile K. Lopez, Elie Robert, et al. “Human Erythroleukemia Genetics and Transcriptomes Identify Master Transcription Factors as Functional Disease Drivers.” Blood 136, no. 6 (August 6, 2020): 698–714.
Rohmer, Julien, Amélie Couteau‐Chardon, Julie Trichereau, Kewin Panel, Cyrielle Gesquiere, Raouf Ben Abdelali, Audrey Bidet, et al. “Epidemiology, Clinical Picture and Long‐term Outcomes of FIP1L1‐PDGFRA‐positive Myeloid Neoplasm with Eosinophilia: Data from 151 Patients.” American Journal of Hematology, July 28, 2020, ajh.25945.
Dumas, Pierre-Yves, Sarah Bertoli, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Thibaut Leguay, et al. “Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.” Cancers 12, no. 8 (July 24, 2020): 2044.
Laurent, Anouchka P., Aurélie Siret, Cathy Ignacimouttou, Kunjal Panchal, M’Boyba Diop, Silvia Jenni, Yi-Chien Tsai, et al. “Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 26, no. 13 (July 1, 2020): 3307–18.
Gerby, Bastien, and Trang Hoang. “A Targetable Cue in T-Cell Malignancy.” Blood 135, no. 19 (May 7, 2020): 1616–17.
Vergez, François, Marie-Laure Nicolau-Travers, Sarah Bertoli, Jean-Baptiste Rieu, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, et al. “CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.” Cancers 12, no. 5 (May 6, 2020): 1174.
Bertoli, Sarah, Pierre-Yves Dumas, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Suzanne Tavitian, et al. “Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study.” Cancers 12, no. 4 (March 25, 2020): 773.
Bertoli, Sarah, Suzanne Tavitian, Emilie Bérard, Véronique Mansat-De Mas, Laetitia Largeaud, Noémie Gadaud, Jean-Baptiste Rieu, et al. “More than Ten Percent of Relapses Occur after Five Years in AML Patients with NPM1 Mutation.” Leukemia & Lymphoma, February 5, 2020, 1–4.
Beziat, Guillaume, Suzanne Tavitian, Sarah Bertoli, Françoise Huguet, Laetitia Largeaud, Isabelle Luquet, François Vergez, et al. “Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations.” European Journal of Haematology 105, no. 3 (2020): 302–7.
Péricart, Sarah, Charlotte Waysse, Aurore Siegfried, Stephanie Struski, Eric Delabesse, Camille Laurent, and Solène Evrard. “Subsequent Development of Histiocytic Sarcoma and Follicular Lymphoma: Cytogenetics and next-Generation Sequencing Analyses Provide Evidence for Transdifferentiation of Early Common Lymphoid Precursor-a Case Report and Review of Literature.” Virchows Archiv: An International Journal of Pathology, December 5, 2019.
Lopez, Cecile K., Esteve Noguera, Vaia Stavropoulou, Elie Robert, Zakia Aid, Paola Ballerini, Chrystele Bilhou-Nabera, et al. “Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.” Cancer Discovery, October 29, 2019.
Largeaud, Laetitia, Sarah Bertoli, Emilie Bérard, Stéphanie Dufrechou, Naïs Prade, Noémie Gadaud, Suzanne Tavitian, et al. “Outcome of Relapsed/Refractory AML Patients with IDH1R132 Mutations in Real Life before the Era of IDH1 Inhibitors.” Leukemia & Lymphoma, September 30, 2019, 1–4.
Bertoli, Sarah, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Eric Delabesse, Thibault Comont, Audrey Sarry, Françoise Huguet, Emilie Bérard, and Christian Récher. “Outcome of Patients Aged 60-75 Years with Newly Diagnosed Secondary Acute Myeloid Leukemia: A Single-Institution Experience.” Cancer Medicine, June 7, 2019.
Comont, T., K. Delavigne, P. Cougoul, S. Bertoli, E. Delabesse, P. Fenaux, and O. Beyne-Rauzy. “[Management of myelodysplastic syndromes in 2019: An update].” La Revue De Medecine Interne, May 1, 2019.
Largeaud, Laetitia, Emilie Bérard, Sarah Bertoli, Stéphanie Dufrechou, Naïs Prade, Noémie Gadaud, Suzanne Tavitian, et al. “Outcome of AML Patients with IDH2 Mutations in Real World before the Era of IDH2 Inhibitors.” Leukemia Research 81 (April 27, 2019): 82–87.
De Barros, Sandra, Flora Vayr, Fabien Despas, Mathilde Strumia, Clémentine Podevin, Martin Gauthier, Eric Delabesse, et al. “The Impact of Chronic Myeloid Leukemia on Employment: The French Prospective Study.” Annals of Hematology 98, no. 3 (March 2019): 615–23.
Bertoli, Sarah, Etienne Paubelle, Emilie Bérard, Estelle Saland, Xavier Thomas, Suzanne Tavitian, Marie-Virginie Larcher, et al. “Ferritin Heavy/Light Chain (FTH1/FTL) Expression, Serum Ferritin Levels, and Their Functional as Well as Prognostic Roles in Acute Myeloid Leukemia.” European Journal of Haematology 102, no. 2 (February 2019): 131–42.
Passet, Marie, Nicolas Boissel, François Sigaux, Colombe Saillard, Mario Bargetzi, Ibrahima Ba, Xavier Thomas, et al. “PAX5 P80R Mutation Identifies a Novel Subtype of B-Cell Precursor Acute Lymphoblastic Leukemia with Favorable Outcome.” Blood 133, no. 3 (17 2019): 280–84.
Fournier, Benjamin, Estelle Balducci, Nicolas Duployez, Emmanuelle Clappier, Wendy Cuccuini, Chloé Arfeuille, Aurélie Caye-Eude, et al. “B-ALL With t(5;14)(Q31;Q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.” Frontiers in Oncology 9 (2019): 1374.

Team members

Jérémy Bigot
Chercheur Post-Doctorant / Post-Doc researcher
Justine Thomas
Doctorant / PhD student
Pauline Enfedaque
Doctorant / PhD student
Philippe Leleux
Chercheur Post-Doctorant / Post-Doc researcher
Antoine Nouhaud
Doctorant / PhD student
Isabelle Luquet
Clinicien Chercheur / Researcher hospital practitioner
Laëtitia Largeaud
Doctorant / PhD student
Esmaa Sellam
Doctorant / PhD student
Stéphanie Dufréchou
Ingénieur de laboratoire / laboratory engineer
Christine Didier
Chercheur statutaire / permanent scientist
Naïs Prade
Ingénieur de laboratoire / laboratory engineer
Marlène Pasquet
Enseignant chercheur / University researcher
Stéphanie Struski
Ingénieur de laboratoire / laboratory engineer
Mathieu Bouttier
Ingénieur de laboratoire / laboratory engineer
Eric Delabesse
Hospitalo-Universitaire / University teacher hospital practitioner
Christel Lauer
Technicien de laboratoire / Laboratory Technician
Cyril Broccardo
Chercheur statutaire / permanent scientist
Sylvie Hebrard
Technicien de laboratoire / Laboratory Technician
Bastien Gerby
Chercheur statutaire / permanent scientist
Camille Hamelle
Ingénieur de laboratoire / laboratory engineer

partnerships & Funding

Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches en Cancérologie de Toulouse (Oncopole)

Toulouse – FR

Nous contacter

05 82 74 15 75

Envie de rejoindre
L’équipe du CRCT ?

Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches contre le Cancer de Toulouse (Oncopole)

Toulouse - FR

Nous contacter

+33 5 82 74 15 75

Nous rejoindre ?

Pin It on Pinterest